ClearBridge Investments, an investment management company, recently released its “ClearBridge Growth Strategy” fourth-quarter 2025 investor letter. The report highlighted the performance of US equities in the fourth quarter, with the S&P 500 Index returning 2.7% and the Russell Midcap Growth Index declining 3.7%. Despite the volatility in the market, ClearBridge Growth Strategy managed to outperform, showcasing a balanced and highly active share approach.
The strategy focused on maintaining a disciplined portfolio management and opportunistic capital allocation, which contributed to its success in capturing early momentum while providing downside protection during periods of rising volatility. In addition, the fund’s top five holdings reflected its best picks for 2025.
One of the highlighted stocks in the investor letter was Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals is a biotechnology company that specializes in developing and commercializing therapies for cystic fibrosis. The stock showed promising returns, with a one-month return of 1.79% and a 12.21% gain over the last 52 weeks. As of January 9, 2026, Vertex Pharmaceuticals closed at $463.86 per share, with a market capitalization of $118.929 billion.
ClearBridge Growth Strategy mentioned Vertex Pharmaceuticals in its investor letter, stating that positive contributions from steadier growth holdings helped offset market pressures. The company’s kidney disease pipeline and innovation-driven growth were highlighted as key factors driving its performance.
While Vertex Pharmaceuticals may not be among the 30 most popular stocks among hedge funds, it continues to attract investor interest. In the third quarter, 61 hedge fund portfolios held shares of Vertex Pharmaceuticals, representing an increase from the previous quarter. The company reported $3.08 billion in revenue in the third quarter, showing an 11% growth compared to the same period in 2024.
Despite the potential of Vertex Pharmaceuticals as an investment, ClearBridge Growth Strategy believes that certain AI stocks offer greater upside potential with less downside risk. Investors seeking opportunities in the AI sector are encouraged to explore undervalued stocks that stand to benefit from current market trends.
In conclusion, ClearBridge Investments’ fourth-quarter 2025 investor letter highlighted the success of its growth strategy and the performance of key holdings like Vertex Pharmaceuticals. As the market continues to evolve, investors are advised to consider a diversified portfolio that aligns with long-term investment goals and market trends.
